OXIGENE INC. (OXGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OXIGENE INC. (OXGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (199)	4/18/2001 12:23:55 PM
From: keokalani'nui	Read Replies (1) of 273

Agents that Inhibit Endothelial Cells Several endogenous angiogenesis inhibitors or agents that directly inhibit endothelial cell proliferation are undergoing phase I/II clinical evaluation, either alone or in combination with chemotherapy (Table 1). These compounds are usually of low molecular weight, except for endostatin, which is a 20 kD C-terminal fragment of collagen XVIII. Phase II clinical trials in several tumor types are under way with thalidomide, despite its withdrawal from sale in 1961 after being held responsible for the birth of hundreds of phocomelus children. A recent phase II study of thalidomide has demonstrated its antitumor activity in patients with refractory multiple myeloma [57]. Although these compounds all directly inhibit endothelial cells, their molecular targets on endothelial cells are diverse. In particular, combretastatin is unique since it induces apoptosis in proliferating endothelial cells, leading to blood flow shutdown to tumors rather than to surrounding normal tissues. theoncologist.alphamedpress.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next